Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16384951 | 0.89 | MAPK14 (0.31) | MAPK14 | |
| SCHEMBL17751230 | 0.89 | NR1H4 (0.33) | CNR2HTR6MAPK1MAPK14MAPKAPK5 | |
| SCHEMBL17886106 | 0.88 | BRD4 (0.32) | NOTUM | |
| SCHEMBL16385565 | 0.88 | PDK2 (0.35) | DRD1 | |
| SCHEMBL17789254 | 0.88 | GRM7 (0.35) | — | |
| SCHEMBL17804267 | 0.87 | DRD1 (0.31) | CNR2NOTUMDRD1 | |
| SCHEMBL17788156 | 0.87 | MAPK14 (0.35) | MAPK14 | |
| SCHEMBL16384952 | 0.87 | ATP4A (0.32) | MAPK14 | |
| SCHEMBL16999058 | 0.85 | HTR1A (0.31) | HTR6NOTUMDRD1 | |
| SCHEMBL18427512 | 0.84 | POLB (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020715-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| WO-2015005499-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | 住友化学株式会社 (JP) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SOD1, UQCRB, MT-CO1 | CNR2 3151/4885HTR6 2049/4885MAPK1 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.